DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies
(Thomson Reuters ONE) -
Press Release
Montrouge, France, June 1, 2016
DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development
in Food Allergies
Nine Presentations Continue to Support the Potential Use of the Viaskin(®)
Technology in Food Allergies
Late-breaking Oral Abstract Highlights Personalized Biomarker Modeling to
Predict Allergy Sensitivity during treatment with Viaskin Peanut
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that data from the company's Viaskin programs, a proprietary technology platform
that can deliver biologically active compounds to the immune system through the
skin, will be featured in nine presentations at the European Academy of Allergy
and Clinical Immunology (EAACI) Congress 2016, taking place in Vienna, Austria,
June 11 - 15, 2016.
Presentations featured at the meeting will highlight progress across DBV's
clinical and scientific programs, as well as Chemistry, Manufacturing and
Control (CMC) activities for Viaskin Peanut, an investigational treatment for
food allergy desensitization based on Epicutaneous Immunotherapy (EPIT®).
"As DBV continues to build a differentiated food allergy franchise based on our
patient- and physician-friendly approach to immunotherapy, we are excited to
present data at EAACI that highlight Viaskin's cutting-edge technology and
science," said Dr. Pierre Henri Benhamou, Chairman and Chief Executive Officer,
DBV Technologies. "We are proud to share our latest findings in critical areas
such as biomarker modeling, which we believe will help our product candidates
meet our patients' individual needs through personalized monitoring."
All abstracts for the EAACI Congress will be published online on June 10, 2016
in Allergy: Online Library
Details for each presentation follow below.
Oral Presentations
"Prediction of Peanut-Challenge Outcome with Biomarkers" Late Breaking Oral
Abstract Session (LBO)
Presenter: Aurélie Peillon, DBV Technologies
Date/Time: June 13 / 3:45 PM - 5:15 PM
Session Title: Determination of Severity and Treatment with Food Allergy
Session Number: LB OAS 4
Location: Lehar 4
"Unique Epigenetic Modulation by EPIT Compared to OIT in a Model of Peanut
Sensitized Mice: Sustainable GAT-3 Hypermethylation and Foxp3 Hypomethylation"
Presenter: Dr. Jorg Tost, Head of Laboratory for Epigenetics and Environment
(LEE), the National Genotyping Center, Genomics Institute/CEA
Date/Time: June 12 / 10:30 AM - 12:00 PM
Session Title: Immune Mechanisms of Allergen-Specific Immunotherapy
Session Number: OAS 1
Location: OAS-Stolz 2
Poster Presentations
"Characterization of Peanut Proteins on a Patch for Epicutaneous Immunotherapy
(EPIT)"
Presenter: Isabelle Pascal, DBV Technologies
Date/Time: June 12 / 12:00 PM - 1:30 PM
Session Title: Allergen immunotherapy: Vaccines and clinical cases
Session Number: TPS 6
Poster Number: 682
Location: Poster Exhibition
"EPIT-Induced Tregs Suppress T-cell Proliferation in Specific and Bystander
Conditions in a Model of Food Allergen Sensitized Mice"
Presenter: Dr. Benjamin Pelletier, DBV Technologies
Date/Time: June 12 / 3:30 PM - 5:00 PM
Session Number: PDS 10
Poster Number: 315
Location: PDS3
Session Title: Mechanisms of Immunotherapy
"EPIT is Safe and Efficacious in Filaggrin Deficient Mice Sensitized to Peanut"
Presenter: Dr. Sophie Wavrin, DBV Technologies
Date/Time: June 12 / 3:30 PM - 5:00 PM
Session Title: Food Allergy: From Mice to Men
Session Number: PDS 9
Poster Number: 300
Location: PDS2
"EPIT-induced Bystander Effect Mainly Conferred by Naïve Tregs via Soluble
Factors and Cell-Cell Contact in a Murine Model"
Presenter: Dr. Lucie Mondoulet, DBV Technologies
Date/Time: June 12 / 3:30 PM - 5:00 PM
Session Title: Mechanisms of Immunotherapy
Session Number: PDS 10
Poster Number: 313
Location: PDS3
"Development and Validation of a Sandwich Enzyme-Linked Immunosorbent Assay
(ELISA) for the Quantification of Ara h6 in Peanut Extract, and Peanut Protein
Patches for Epicutaneous Immunotherapy (EPIT)"
Presenter: Isabelle Pascal, DBV Technologies
Date/Time: June 12 / 3:30 PM - 5:00 PM
Session Title: Mechanisms of Immunotherapy
Session Number: PDS 10
Poster Number: 319
Location: PDS3
"Epicutaneous Immunotherapy but not Oral Immunotherapy Prevents Eosinophilic
Infiltration in the Esophagus in a Model of Milk Sensitized Mice"
Presenter: Dr. Lucie Mondoulet, DBV Technologies
Date/Time: June 13 / 10:45 AM - 12:15 PM
Session Title: Innovations in Allergen-Specific Immunotherapy
Session Number: PDS 12
Poster Number: 340
Location: PDS2
"Gut Homing Receptors Designate Epicutaneous Immunotherapy as the Most
Appropriate Route for the Treatment of Food Allergy in a Model of Peanut
Sensitized Mice"
Presenter: Dr. Vincent Dioszeghy, DBV Technologies
Date/Time: June 13 / 10:45 AM - 12:15 PM
Session Title: Innovations in Allergen Specific Immunotherapy
Session Number: PDS 12
Poster Number: 338
Location: PDS2
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements, including statements
about the potential safety and efficacy of Epicutaneous Immunotherapy (EPIT®)
via Viaskin®. These forward-looking statements that are not promises or
guarantees and involve substantial risks and uncertainties. The Company's
product candidates have not been approved for sale in any jurisdiction. Among
the factors that could cause actual results to differ materially from those
described or projected herein are uncertainties associated generally with
research and development, clinical trials and related regulatory reviews and
approvals, the risk that historical preclinical results may not be predictive of
future clinical trial results, and the risk that historical clinical trial
results may not be predictive of future trial results. A further list and
description of these risks, uncertainties and other risks can be found in the
Company's regulatory filings with the French Autorité des Marchés Financiers,
the Company's Securities and Exchange Commission filings and reports, including
in the Company's Annual Report on Form 20-F for the year ended December
31, 2015 and future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. DBV Technologies undertakes
no obligation to update or revise the information contained in this Press
Release, whether as a result of new information, future events or circumstances
or otherwise.
DBV Technologies Contacts
Susanna Mesa
Senior Vice President, Strategy
Tel. : +1 212-271-0861
susanna.mesa(at)dbv-technologies.com
DBV Technologies Media Contacts US & Europe
Marion Janic Caroline Carmagnol
Rooney & Associates Alize RP - Relation Presse
Tel. : +1-212-223-4017 Tel. : +33(0)6 64 18 99 59
mjanic(at)rooneyco.com caroline(at)alizerp.com
Erinn White
Centron PR
Tel. : +1-646-722-8822
ewhite(at)centronpr.com
PDF Version:
http://hugin.info/156437/R/2016959/748258.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#2016959]
Unternehmensinformation / Kurzprofil:
Datum: 01.06.2016 - 07:31 Uhr
Sprache: Deutsch
News-ID 474799
Anzahl Zeichen: 10371
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 302 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
